Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.65 |
| ▸ | LGALS3 | P17931 | 4/20 | 0.42 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.42 |
| ▸ | LGALS7; LGALS7B | P47929 | 2/20 | 0.42 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.38 |
| ▸ | AMY2A | P04746 | 1/20 | 0.38 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | HRAS | P01112 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27628029 | 0.91 | KMT2A (0.61) | KMT2AMEN1L3MBTL1ALDH1A1AMY2A | |
| SCHEMBL797057 | 0.91 | KMT2A (0.61) | KMT2AMEN1L3MBTL1ALDH1A1AMY2A | |
| SCHEMBL15883911 | 0.91 | KMT2A (0.61) | KMT2AMEN1L3MBTL1ALDH1A1AMY2A | |
| SCHEMBL10292495 | 0.91 | KMT2A (0.61) | KMT2AMEN1L3MBTL1ALDH1A1AMY2A | |
| SCHEMBL7762220 | 0.88 | KMT2A (0.59) | KMT2AMEN1L3MBTL1LGALS3LGALS1 | |
| SCHEMBL14683525 | 0.87 | MEN1 (0.55) | KMT2AMEN1L3MBTL1LGALS3LGALS9 | |
| SCHEMBL12453774 | 0.87 | MEN1 (0.55) | KMT2AMEN1L3MBTL1LGALS3LGALS8 | |
| SCHEMBL15473933 | 0.87 | MEN1 (0.55) | KMT2AMEN1L3MBTL1LGALS3LGALS8 | |
| SCHEMBL14685773 | 0.87 | MEN1 (0.55) | KMT2AMEN1L3MBTL1LGALS3LGALS8 | |
| SCHEMBL16018595 | 0.86 | KMT2A (1.00) | KMT2AMEN1L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170275389-A1 | NOVEL GLYCAN CONJUGATES AND USE THEREOF | ACADEMIA SINICA (TW) | 2017-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170275389-A1 | NOVEL GLYCAN CONJUGATES AND USE THEREOF | STT3B, ST3GAL3, FUT6 | KMT2A 3208/4885MEN1 1982/4885L3MBTL1 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.